Hoth Therapeutics Files 10-Q, Remains Pre-Revenue Biotech

TL;DR

**HOTH is still a pre-revenue biotech burning cash; don't expect profits anytime soon.**

AI Summary

Hoth Therapeutics, Inc. (HOTH) reported no revenue for the quarter ended June 30, 2025, consistent with its pre-revenue biotechnology status. The company continues to operate at a net loss, reflecting ongoing research and development expenditures. No specific net income figures or percentage changes were provided in the excerpt, but the company's status as a 'smaller reporting company' and 'non-accelerated filer' suggests limited financial scale. Key business changes were not detailed in the provided text, but the company's primary focus remains on pharmaceutical preparations. Risks include the inherent uncertainties of drug development and the need for significant capital, though specific risk factors were not enumerated here. The strategic outlook, while not explicitly stated, involves advancing its therapeutic pipeline, as implied by its industry classification. The company maintains its listing on The Nasdaq Stock Market LLC under the symbol HOTH.

Why It Matters

For investors, Hoth Therapeutics' continued pre-revenue status means its valuation is entirely speculative, tied to future drug development milestones rather than current financial performance. Employees face job security tied to successful clinical trials and funding, while customers (future patients) await potential new therapies. The broader market sees HOTH as a small player in the highly competitive pharmaceutical preparations sector, where larger firms like Pfizer or Johnson & Johnson dominate. Its success or failure could slightly impact the biotech sub-sector's sentiment for early-stage companies.

Risk Assessment

Risk Level: high — Hoth Therapeutics is a 'smaller reporting company' and 'non-accelerated filer' with no revenue, indicating a high-risk profile typical of early-stage biotechnology firms. The absence of revenue means the company relies entirely on external funding or existing capital to sustain operations and drug development, posing significant liquidity risks.

Analyst Insight

Investors should approach Hoth Therapeutics with extreme caution, recognizing it as a highly speculative investment. Only those with a high-risk tolerance and a long-term horizon, willing to bet on potential future drug approvals, should consider a position. Monitor R&D updates and financing activities closely.

Financial Highlights

debt To Equity

N/A

revenue

$0

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

N/A

eps

N/A

gross Margin

N/A

cash Position

N/A

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue (Hoth Therapeutics reported no revenue for the quarter ended June 30, 2025, indicating its pre-commercial stage.)
• 10-Q — Form Type (The company filed a Quarterly Report, providing an update on its financial condition and operations for the quarter.)
• 001-38803 — Commission File Number (This unique identifier is used by the SEC for Hoth Therapeutics' filings.)
• 20250630 — Conformed Period of Report (The financial data covers the period ending June 30, 2025.)
• 251206903 — Film Number (An internal SEC identifier for the filing.)

Key Players & Entities

• Hoth Therapeutics, Inc. (company) — registrant filing 10-Q
• The Nasdaq Stock Market LLC (company) — exchange where HOTH common stock is registered
• 001-38803 (regulator) — Commission File Number
• June 30, 2025 (date) — end of the quarterly period reported
• Nevada (company) — state of incorporation for Hoth Therapeutics
• 1177 Avenue of the Americas (company) — business address of Hoth Therapeutics
• New York (company) — city of Hoth Therapeutics' business address
• 82-1553794 (company) — IRS Employer Identification No. for Hoth Therapeutics
• 03 Life Sciences (company) — organization name associated with the filer
• 2025-08-12T00:00:00.000Z (date) — filing date of the 10-Q

FAQ

Risk Factors

• Need for Significant Capital [high — financial]: As a pre-revenue biotechnology company, Hoth Therapeutics requires substantial capital to fund its research and development activities, clinical trials, and eventual commercialization. Failure to secure adequate funding could impede or halt its progress.
• Drug Development Uncertainty [high — operational]: The development of pharmaceutical products is inherently uncertain and subject to numerous risks, including the failure to demonstrate safety and efficacy in clinical trials, regulatory hurdles, and market acceptance. These uncertainties can lead to significant delays and increased costs.
• Regulatory Approval Process [high — regulatory]: Obtaining regulatory approval from bodies like the FDA is a complex, lengthy, and expensive process. Delays or failures in this process can significantly impact the company's ability to bring its products to market.

Industry Context

Hoth Therapeutics operates within the pharmaceutical preparations industry, a sector characterized by high research and development costs, lengthy product development cycles, and significant regulatory oversight. The competitive landscape includes numerous companies, from large established pharmaceutical giants to smaller biotech firms, all vying for market share and therapeutic breakthroughs. Key industry trends involve advancements in drug discovery technologies, personalized medicine, and increasing focus on biologics and novel therapeutic modalities.

Regulatory Implications

As a biotechnology company, Hoth Therapeutics is subject to stringent regulatory requirements from agencies like the FDA. The process of drug development, clinical trials, and eventual market approval involves significant compliance obligations. Any missteps or delays in regulatory processes can have severe financial and operational consequences.

What Investors Should Do

1. Monitor cash burn rate and future funding rounds.
2. Evaluate progress in drug development pipeline.
3. Assess the competitive landscape and market potential for its lead candidates.

Key Dates

• 2025-06-30: Quarterly Period End — This date marks the end of the reporting period for the 10-Q filing, providing financial and operational data up to this point.
• 2025-08-12: 10-Q Filing Date — The date the company officially filed its Quarterly Report with the SEC, making the information publicly available.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a continuing disclosure of financial and other information for the issuer's fiscal quarter. (This filing provides the latest financial and operational update for Hoth Therapeutics.)

Smaller Reporting Company

A company that meets certain criteria related to public float and annual revenue, allowing for scaled disclosure requirements. (Indicates Hoth Therapeutics has a limited financial scale and may have less stringent reporting obligations.)

Non-accelerated filer

A type of filer that is not a large accelerated filer or an accelerated filer, typically indicating a smaller company with less public float and revenue. (Further emphasizes Hoth Therapeutics' smaller size and potentially less extensive financial reporting compared to larger companies.)

Pharmaceutical Preparations

Products manufactured for use as medicines or drugs. (This is the Standard Industrial Classification (SIC) code for Hoth Therapeutics, indicating its primary business focus.)

Year-Over-Year Comparison

The provided 10-Q filing for the period ending June 30, 2025, indicates no revenue, consistent with the company's pre-commercial biotechnology status. Specific comparative figures for net income, margins, or asset/debt levels against the prior year's filing are not detailed in this excerpt. However, the company's continued operation as a smaller reporting company and non-accelerated filer suggests a consistent financial scale. No new specific risk factors were enumerated in the provided text, but the inherent risks of drug development and capital requirements remain central.

Key Financial Figures

• $0.0001 — ange on which registered Common Stock, $0.0001 par value HOTH The Nasdaq Stock Market

Filing Documents

• ea0249801-10q_hoth.htm (10-Q) — 707KB
• ea024980101ex31-1_hoth.htm (EX-31.1) — 11KB
• ea024980101ex31-2_hoth.htm (EX-31.2) — 11KB
• ea024980101ex32-1_hoth.htm (EX-32.1) — 4KB
• ea024980101ex32-2_hoth.htm (EX-32.2) — 4KB
• 0001213900-25-074968.txt ( ) — 4907KB
• hoth-20250630.xsd (EX-101.SCH) — 47KB
• hoth-20250630_cal.xml (EX-101.CAL) — 27KB
• hoth-20250630_def.xml (EX-101.DEF) — 231KB
• hoth-20250630_lab.xml (EX-101.LAB) — 429KB
• hoth-20250630_pre.xml (EX-101.PRE) — 249KB
• ea0249801-10q_hoth_htm.xml (XML) — 570KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 1 ITEM 1.

Financial Statements

Financial Statements 1 Condensed Consolidated Balance Sheets as of June 30, 2025 (Unaudited) and December 31, 2024 1 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Six Months Ended June 30, 2025 and 2024 (Unaudited) 2 Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Six Months Ended June 30, 2025 and 2024 (Unaudited) 3 Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2025 and 2024 (Unaudited) 4 Notes to Unaudited Condensed Consolidated Financial Statements 5 ITEM 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 ITEM 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 29 ITEM 4.

Controls and Procedures

Controls and Procedures 29

- OTHER INFORMATION

PART II - OTHER INFORMATION 30 ITEM 1.

Legal Proceedings

Legal Proceedings 30 ITEM 1A.

Risk Factors

Risk Factors 30 ITEM 2. Unregistered Sales of Equity Securities and Use of Proceeds 30 ITEM 3. Defaults Upon Senior Securities 30 ITEM 5. Other Information 30 ITEM 6. Exhibits 31

SIGNATURES

SIGNATURES 32 i CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY DATA This Quarterly Report on Form 10-Q contains certain forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Any statements in this Quarterly Report on Form 10-Q about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and are forward-looking statements. These statements are often, but not always, made through the use of words or phrases such as "may," "should," "believes," "will," "expects," "anticipates," "estimates," "predicts," "potential," "continues" "intends," "plans" and "would" or the negative of these terms or other comparable terminology. For example, statements concerning financial condition, possible or assumed future results of operations, growth opportunities, industry ranking, plans and objectives of management, markets for our common stock and future management and organizational structure are all forward-looking statements. Our forward-looking results or performance and involve substantial risks and uncertainty. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from any results, levels of activity, performance or achievements expressed or implied by any forward-looking statement. We may not actually achieve the plans, intentions or expectations disclosed in these forward-looking statements. Any forward-looking statements are qualified in their entirety by reference to the risk factors discussed in this Quarterly Report on Form 10-Q. Our business and our

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

FINANCIAL STATEMENTS

ITEM 1. FINANCIAL STATEMENTS. HOTH THERAPEUTICS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS June 30, December 31, 2025 2024 (Unaudited) ASSETS CURRENT ASSETS: Cash and cash equivalents $ 9,014,108 $ 7,038,923 Prepaid expenses and other current assets 1,038,794 605,948 Total Current Assets 10,052,902 7,644,871 NON-CURRENT ASSETS: Operating lease right-of-use asset, net 18,081 31,075 Investment in joint ventures at fair value 36,819 36,819 Total Non-Current Assets 54,900 67,894 Total Assets $ 10,107,802 $ 7,712,765 LIABILITIES AND STOCKHOLDERS' EQUITY CURRENT LIABILITIES: Accounts payable $ 75,510 $ 412,071 Accrued expenses 267,794 390,760 Operating lease liability, current portion 21,326 28,366 Total Current Liabilities 364,630 831,197 LONG-TERM LIABILITIES: Operating lease liability, less current portion - 2,709 Total Long-Term Liabilities - 2,709 Total Liabilities 364,630 833,906 Commitments and Contingencies (Note 6) STOCKHOLDERS' EQUITY: Preferred stock, $ 0.0001 par value, 10,000,000 shares authorized; 3,000,000 shares undesignated; 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024 - - Series A Convertible Preferred Stock, $ 0.0001 par value; 5,000,000 shares designated; 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024 - - Series B Preferred Stock, $ 0.0001 par value; 2,000,000 shares designated; 0 shares issued and outstanding as of June 30, 2025 and December 31, 2024 - - Common stock, $ 0.0001 par value; 50,000,000 shares authorized; 13,234,027 and 8,042,747 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively 1,323 804 Additional paid-in capital 75,815,158 67,279,033 Accumulated deficit ( 66,085,353 ) ( 60,410,041 ) Accumulated other comprehensive income 12,044 9,063 Total Stockholders' Equity 9,743,172 6,878,859 Total Liabilities and Stockholders'

View Full Filing

View this 10-Q filing on SEC EDGAR